Close Menu

More articles about Infectious Disease

A Roche official said that a "very substantial" portion of the 24 percent growth in qPCR and NAP systems could be attributed to H1N1, with the largest growth in instruments.

The newest authorization allows testing on 3M's molecular diagnostic system.

BD and Tyrian ended their partnership to develop a point-of-care diagnostic for active tuberculosis because of an inability to consistently detect Tyrian's lead protein biomarker in clinical samples at high enough sensitivity and specificity levels.

The company will collaborate with UC Davis to develop a test for eight microbes that cause sepsis in burn and wound patients.

The company said it is working with the City of Hope to investigate the vector-based delivery of an anti-HIV RNA cocktail composed of pHIV7, an shRNA targeting an exon in HIV-1 tat/rev, and a Tar decoy.

Last week's ruling "is a complete victory for Roche," an attorney for the company told GenomeWeb Daily News.

The agreement covers systems for HIV and hepatitis B management.

The company will use $2.2 million to develop a PCR-based multiple flu test.

Exiqon said that it has achieved several milestones in a collaboration with Tacere Therapeutics, including the completion of a series of customizable assays for the detection of therapeutic shRNAs currently under development through a partnership between Tacere and Pfizer.

The $600,000 award also strengthens Inviragen's ties to UW-Madison. The company's CSO maintains an academic appointment and a research lab within the School of Veterinary Medicine, which has collaborated with Inviragen on other projects.

Biron will market and distribute the Warnex H1N1 flu diagnostic to industrial customers.

The companies have now “put together the final project plan, budgets, and agreements” for the HBV effort, according to Benitec’s CEO.

The recommendations cover performance for studies, detection, repeatability, and other practices.

In an interview with Pharmacogenomics Reporter this week, Hakan Sakul provided a snapshot of Pfizer's efforts in personalized medicine, the company's stance on regulatory issues, and its overall focus on "omics"-guided medicine.

The $200,000 grant also dovetails with an existing grant under which the University of Oklahoma Health Sciences Center and Pure Vaccine Solutions aim to look for new disease-specific biomarkers for West Nile virus. Both Receptor Logic and Pure Vaccine Solutions are portfolio companies of VC shop Emergent Technologies.

This is the second vaccine-development partnership struck between Advaxis and City of Hope in as many years, further cementing an ongoing and mutually beneficial research partnership between the company and the cancer research center, according to an Advaxis executive.

Prodesse can add claims to its assay regarding its ability to identify as Influenza A positive specimens conatining the 2009 H1N1 inlfuenza virus.

Schering-Plough owns the IP rights to the drug-response marker and is contemplating further developing and marketing a diagnostic based on it that could accompany its current marketed interferon-based HCV treatment.

Using an siRNA screen, a team of researchers from Boston and Maryland has identified a host of human proteins that appear to play a role in hepatitis C infection.

Pages

As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.

BBC News says the uncertainty over Brexit is affecting science funding in the UK.

A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.

In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.